Livzon Pharmaceutical Group (HK:1513) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group Inc. has just received approval from the National Medical Products Administration for a new indication of their drug, Triptorelin Acetate Microspheres for Injection, specifically for the treatment of endometriosis. This marks a significant milestone for the company, expanding the potential market for their product and offering a new therapeutic option for individuals suffering from this condition.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.